Circulating levels of allopregnanolone, a neuroactive steroid, and leptin during treatment with valproic acid in children with epilepsy

Neuroendocrinology

Volumn 93, Issue 3, 2011, Pages 159-164

  Grosso, Salvatore ^a   Luisi, Stefano ^a   Mostardini, Rosa ^a   Matera, Mariarosaria ^b   Barlocco, Enzo Gabriele ^b   Casarosa, Elena ^c   Balestri, Paolo ^a   Petraglia, Felice ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Antiepileptic drug; Eating disorders; Epilepsy; Obesity

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; LEPTIN; VALPROIC ACID;

ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; LEAN BODY WEIGHT; MALE; OBESITY; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION;

ANTICONVULSANTS; CHILD; EPILEPSY; FEMALE; HUMANS; IMMUNOASSAY; LEPTIN; MALE; OBESITY; PREGNANOLONE; VALPROIC ACID; WEIGHT GAIN;

EID: 79953747949     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321664     Document Type: Article

References (40)

1. Bialer M, Yagen B: Valproic acid: second generation. Neurotherapeutics 2007;4:130-137. (Pubitemid 46107326)
2. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG: Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-924. (Pubitemid 24083217)
3. Pylvänen V, Pakarinen A, Knip M, et al: Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-648.
4. Verrotti A, la Torre R, Trotta D, Mohn A, Chiarelli F: Valproate-induced insulin resistance and obesity in children. Horm Res 2009;71:125-131.
5. Wirrell EC: Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28:126-129.
6. Hamed SA, Fida NM, Hamed EA: States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. Eur J Paediatr Neurol 2009;13:261-268.
7. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salvestroni C, Tonetti A, Nappi RE, Luisi S, Palumbo M, Purdy RH, Luisi M: Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-2103. (Pubitemid 28496343)
8. Mellon SH, Vaudry H: Biosynthesis of neurosteroids and regulation of their synthesis. Int Rev Neurobiol 2001;46:33-78. (Pubitemid 33798717)
9. Jung-Testas I, Hu ZY, Baulieu EE, Robel P: Neurosteroids: biosynthesis of pregnenolone and progesterone in primary cultures of rat glial cells. Endocrinology 1989;125:2083-2091. (Pubitemid 19258646)
10. Purdy RH, Morrow AL, Moore PH Jr, Paul SM: Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci USA 1991;88:4553-4557. (Pubitemid 21914579)
11. Lambert JJ, Belelli D, Hill-Venning C, Peters JA: Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 1995;16:295-303.
12. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM: Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986;232:1004-1007. (Pubitemid 16085410)
13. Robichaud M, Debonnel G: Allopregnanolone and ganaxolone increase the firing activity of dorsal raphe nucleus serotonergic neurons in female rats. Int J Neuropsychopharmacol 2006;9:191-200. (Pubitemid 43255832)
14. Grosso S, Luisi S, Berardi R, Mostardini R, Cordelli DM, Morgese G, Petraglia F, Balestri P: Post-ictal circulating levels of allopregnanolone in children with partial or generalized seizures. Epilepsy Res 2005;63:97-102.
15. Grosso S, Luisi S, Mostardini R, Farnetani M, Cobellis L, Morgese G, Balestri P, Petraglia F: Inter-ictal and post-ictal circulating levels of allopregnanolone, an anticonvulsant metabolite of progesterone, in epileptic children. Epilepsy Res 2003;54:29-34. (Pubitemid 36556195)
16. Dubrovsky BO: Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:169-192.
17. Stein D, Maayan R, Loewenthal R, Weizman A: Neurosteroid derangement in women diagnosed with eating disorders;in Ritsner MS, Weizman A (eds): Neuroactive Steroids in Brain Function, Behavioral and Neuropsychiatric Disorders. Berlin, Springer, 2008, pp 493-507.
18. Pham J, Porter J, Svec D, Eiswirth C, Svec F: The effect of dehydroepiandrosterone on Zucker rats selected for fat food preference. Physiol Behav 2000;70:431-441.
19. Iughetti L, Predieri B, Cobellis L, Luisi S, Luisi M, Forese S, Petraglia F, Bernasconi S: High serum allopregnanolone levels in girls with precocious puberty. J Clin Endocrinol Metab 2002;87:2262-2265. (Pubitemid 34521518)
20. Commission on Classification and Terminology of the International League against Epilepsy. Proposal for revised classification of epilepsies and patients with epilepsy syndromes. Epilepsia 1989;30:3890-3899.
21. Engel J Jr: International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796-803.
22. Jallon P, Picard F: Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978. (Pubitemid 33097097)
23. Ben-Menachem E: Weight issues for people with epilepsy - a review. Epilepsia 2007;48(suppl 9):42-45.
24. Biton V: Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-791.
25. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1240-1243. (Pubitemid 30240471)
26. Demir E, Aysun S: Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22:361-364. (Pubitemid 30410787)
27. Grosso S, Mostardini R, Piccini B, Balestri P: Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother 2009;43:45-50.
28. Egger J, Brett EM: Effects of sodium valproate in 100 children with special reference to weight. Br Med J 1981;283:577-581. (Pubitemid 11052923)
29. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584. (Pubitemid 26143595)
30. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI: Serum insulin and leptin levels in valproateassociated obesity. Epilepsia 2002;43:514-517. (Pubitemid 34533707)
31. Klein KM, Hamer HM, Reis J, et al: Weight change in monozygotic twins treated with valproate. Obes Res 2005;13:1330-1334.
32. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Ernst B, Hoppichler F, Karall D, Ebenbichler CF, Rostasy K, Luef G: Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 2008;49:353-357. (Pubitemid 351172010)
33. Rauchenzauner M, Haberlandt E, Scholl-Bürgi S, Karall D, Schoenherr E, Tatarczyk T, Engl J, Laimer M, Luef G, Ebenbichler CF: Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 2008;80:142-149.
34. Monteleone P, Luisi M, Colurcio B, Casarosa E, Monteleone P, Ioime R, Genazzani AR, Maj M: Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa. Psychosom Med 2001;63:62-68. (Pubitemid 32125358)
35. Monteleone P, Luisi M, De Filippis G, Colurcio B, Monteleone P, Genazzani AR, Maj M: Circulating levels of neuroactive steroids in patients with binge eating disorder: a comparison with nonobese healthy controls and non-binge eating obese subjects. Int J Eat Disord 2003;34:432-440. (Pubitemid 37339750)
36. Predieri B, Luisi S, Casarosa E, De Simone M, Balli F, Bernasconi S, Rossi M, Petraglia F, Iughetti L: High basal serum allopregnanolone levels in overweight girls. Int J Obes 2007;31:543-549.
37. Fudge MA, Kavaliers M, Ossenkopp KP: Allopregnanolone produces hyperphagia by reducing neophobia without altering food palatability. Eur Neuropsychopharmacol 2006;16:272-280.
38. Griffin LD, Mellon SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 1999;96:13512-13517.
39. A receptors. Psychoneuroendocrinology 2009;34(suppl 1):S48-S58.
40. Martin CK, Han H, Anton SD, Greenway FL, Smith SR: Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. J Psychopharmacol 2009;23:814-825.